Pharmcophore-DOS · Pharmacophore guided diversity-oriented synthesis and its application in discovering inhibitors of protein-protein interactions between RAD51 and BRCA2
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2015-06-01 → 2017-05-31
- EU contribution
- €195,455
- Participants
- 1
- Scheme
- MSCA-IF-EF-ST
Lines connect the coordinator with its partners.
Results in brief
Pharmacophore guided diversity-oriented synthesis and its application in discovering inhibitors of protein-protein interactions between RAD51 and BRCA2
Given the difficulty in drug discovery, in particular when protein-protein interactions are targeted, we proposed a innovative strategy to identify hits and lead compounds for non- or difficult-drugged targets. Such an approach could accelerate the drug discovery and enhance the possibility of success in launching novel therapy to suffering patients. In our research, this novel strategy was developed and validated, and is hopeful to be expanded to more targets.
Data: CORDIS, © European Union
Project objective
The proposed research aims at discovering inhibitors of protein-protein interaction (PPI) between RAD51 and BRCA2 as a promising treatment of cancer, in particular to reverse the resistance of cancer cells to radiotherapy and cytotoxic chemotherapy. The pharmacophore guided DOS approach developed in this project has the potential to be a general method for rational discovery of PPI modulators. The researcher will acquire novel technologies and develop new skills in both scientific and management aspects, which are important in his professional maturity and career plans; while the host can also be benefitted from his experience in medicinal chemistry. This action will promote the mobility inside the European Research Area and spark lasting cooperation among different European countries.
Original text from CORDIS.
Participants
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE · CAMBRIDGECoordinatorUnited Kingdom
Links
Data: CORDIS, © European Union